Bio-Engineered Supplements & Nutrition, Inc. ompany makes bodybuilding supplements and sports nutrition products that are distributed in 70 countries. Its line of about 12 supplements come in capsules, liquids, and powders, and they're sold online or at retailers such as GNC. BSN uses professional bodybuilders who act as spokesmodels to sell the products. It recently teamed up with the Ultimate Fighting Championship for a cross-promotional marketing campaign. The company also sells men's and women's clothing and accessories under the TLF Apparel brand (for Train Like A Freak). BSN was founded in 2001 by President and CEO Chris Ferguson.

Taro Pharmaceutical Industries manufactures drugs for cardiac, dermatological, neurological, and pediatric illnesses. It makes generic prescription and over-the-counter drugs at facilities in Canada, Ireland, Israel, the UK, and the US. It specializes in generics, but also produces private label and branded drugs. Its facilities are capable of producing topical, oral, and injectable formulations. The company also produces active pharmaceutical ingredients for use by its own facilities and sold to other drug makers. Taro Pharmaceutical routinely reinvests more than 10% of its sales into research into the development of new products. Its customers include large drugstore and grocery chains and discount retailers.

Titan Pharmaceuticals thinks big. The development-stage firm is working on drug treatments for large pharmaceutical markets, including central nervous system disorders like chronic pain, Parkinson's disease, and schizophrenia. On its own, the company is developing Probuphine, which may treat opioid addiction; Probuphine combines an already-approved chemical compound with Titan's continuous-release drug delivery technology called ProNeura. Titan is working with Vanda Pharmaceuticals on late-stage compound Iloperidone, a possible treatment for schizophrenia.

Gentronix is a biotechnology company that provides pharmaceutical makers with drug development products and monitoring services. Gentronix's products and services are geared toward helping drug discovery scientists speed up pre-clinical research and development. The company's main product, Greenscreen, uses cellular biosensor technology to test potential pharmaceutical compounds for genotoxicity (DNA damage) and cytotoxicity (general cellular damage). The company was founded in 1999 as part of the University of Manchester Institute of Science and Technology's Biomolecular Sciences and Instrumentation & Analytical Science departments.

Cephalon, Inc. was founded in 1987 and is headquartered in Frazer, Pennsylvania. Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The company's pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa.

Wockhardt works hard in the pharmaceutical world. The research and pharmaceutical manufacturing firm employs more than 500 scientists who focus on recombinant biopharmaceuticals, generics, and new drug discovery. Wockhardt's products include injectables, tablets, liquids, and topicals (creams and ointments) that it manufactures to sell itself and for AstraZeneca, Sanofi-Aventis, Cell Therapeutics, Schering-Plough, and other major drug companies. It operates 15 manufacturing plants in India, the UK, Ireland, France, and the US, and has filed more than 250 patents for biotechnology products. The company is a subsidiary of Khorakiwala Holdings and Investments.

Intervet/Schering-Plough Animal Health company develops, manufactures, and markets veterinary vaccines and pharmaceutical products. Its product portfolio includes vaccines for use in pets, livestock, poultry and aquaculture; treatment lines include antiparasitics, anti-infectives, and endocrine products. Intervet/Schering-Plough Animal Health also develops feed additives and animal productivity enhancers. Intervet/Schering-Plough Animal Health operates in more than 50 countries and sells its products around the world. Intervet/Schering-Plough Animal Health company is a subsidiary of Merck.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Since its inception in 1982, AIM International, Inc. has made and marketed food concentrates and nutritional supplements through direct sales and through "members" who sell and distribute in a multilevel marketing arrangement. On the company's 25th anniversary, CEO Dennis Itami added a personal-care line to the product mix. The company's roster also includes a line of supplements for athletes. AIM International (dba The AIM Companies) has offices in Australia, Canada, New Zealand, South Africa, and the UK. Lead products include AIM BarleyLife and AIMega.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.